Skip to content

Clinical trials

Completed Phase 2 Anemia, Refractory, with Excess of Blasts trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Anemia, Refractory, with Excess of Blasts Phase: Phase 2 Status: Completed Clear all

80 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20006
20016
20024
20037
20046
20055
20063
20073
20082
20093
20105
20111
20122
20131
20142
20152
20171
20182

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed80

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center8
National Cancer Institute (NCI)6
Memorial Sloan Kettering Cancer Center5
Case Comprehensive Cancer Center4
Roswell Park Cancer Institute4
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4
David Rizzieri, MD3
National Heart, Lung, and Blood Institute (NHLBI)3
Alliance for Clinical Trials in Oncology2
Asan Medical Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Anemia, Refractory, with Excess of Blasts80
Myelodysplastic Syndromes58
Leukemia51
Leukemia, Myelomonocytic, Chronic45
Leukemia, Myeloid, Acute41
Precursor Cell Lymphoblastic Leukemia-Lymphoma34
Anemia, Refractory33
Myeloproliferative Disorders27
Leukemia, Myeloid, Accelerated Phase24
Leukemia, Myeloid, Chronic-Phase24

Trials

Showing 1 to 25 of 80. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.